ArticleScientific reports2019
Increased abundance of proteobacteria in aggressive Crohn's disease seven years after diagnosis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Specific alterations in the gut microbiome and metabolome across disease locations of Crohn's disease: a systematic review.BMC gastroenterology · 2026Pooled it
- Trial
- β-Sitosterol β-D-glucoside (BSSG) triggers intestinal inflammation in zebrafish and mouse models prior to neurodegeneration onset.Journal of biomedical science · 2026Article
- Microbiome modulating remedies for chronic diseases: a review of current interventions and future directions.Inflammopharmacology · 2026Review
- The dual role of intestinal parasites in shaping human gut microbiota: distinguishing helminthic and protozoan dynamics.Gut pathogens · 2026Review
- MaAsLin 3: refining and extending generalized multivariable linear models for meta-omic association discovery.Nature methods · 2026Article
- Mycotoxins, gut microbiota alterations and liver disease in animals: A scoping review.Cell biology and toxicology · 2026Review
- Interplay of Microbiome, Oxidative Stress and Inflammation in Health and Disease.Antioxidants (Basel, Switzerland) · 2026Review
- Luohuazizhu Granules Alleviate Symptoms of Ulcerative ColitisCombinatorial chemistry & high throughput screening · 2026Article
- Virome drift in ulcerative colitis patients: faecal microbiota transplantation results in minimal phage engraftment dominated by microviruses.Gut microbes · 2025Article
- TMAO and the gut microbiome: implications for the CVD-CKD-IBD axis.Annals of medicine · 2025Review
- The association of proton pump inhibitors and inflammatory bowel disease from the perspective of gut microbiota perturbation.NPJ biofilms and microbiomes · 2025Review
- From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD's Cardiometabolic Risks.Current atherosclerosis reports · 2025Review
- Spatial host-microbiome profiling demonstrates bacterial-associated host transcriptional alterations in pediatric ileal Crohn's disease.Microbiome · 2025Article
- Microbiome, dysbiosis and use of probiotics in various diseases.World journal of virology · 2025Review
- The microbiome of pseudomyxoma peritonei: a scoping review.Pleura and peritoneum · 2025Review
- Tas2r105 ameliorates gut inflammation, possibly through influencing the gut microbiota and metabolites.mSystems · 2025Article
- Host-Microbiota-Parasite Interactions in Grass Carp: Insights fromMicroorganisms · 2025Article
- Odoribacter splanchnicus-derived extracellular vesicles alleviate inflammatory bowel disease by modulating gastrointestinal inflammation and intestinal barrier function via the NLRP3 inflammasome suppression.Molecular medicine (Cambridge, Mass.) · 2025Article
- Carbon dioxide enhances Akkermansia muciniphila fitness and anti-obesity efficacy in high-fat diet mice.The ISME journal · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal dysbiosis in inflammatory bowel disease (IBD) patients depend on disease activity. We aimed to characterize the microbiota after 7 years of follow-up in an unselected cohort of IBD patients according to disease activity and disease severity. Fifty eight Crohn's disease (CD) and 82 ulcerative colitis (UC) patients were included. Disease activity was assessed by the Harvey-Bradshaw Index for CD and Simple Clinical Colitis Activity Index for UC. Microbiota diversity was assessed by 16S rDNA MiSeq sequencing. In UC patients with active disease and in CD patients with aggressive disease the richness (number of OTUs, p = 0.018 and p = 0.013, respectively) and diversity (Shannons index, p = 0.017 and p = 0.023, respectively) were significantly decreased. In the active UC group there was a significant decrease in abundance of the phylum Firmicutes (p = 0.018). The same was found in CD patients with aggressive disease (p = 0.05) while the abundance of Proteobacteria phylum showed a significant increase (p = 0.03) in CD patients. We found a change in the microbial abundance in UC patients with active disease and in CD patients with aggressive disease. These results suggest that dysbiosis of the gut in IBD patients is not only related to current activity but also to the course of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.